knowledge -WSS

knowledge

author：comprehensive 2025-09-28 20:32:32 - browse：21

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Readout LOUD podcast: mifepristone case, GLP

WSS

Vertex Pharmaceuticals may move headquarters in Boston

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

White House drug czar issues call for 'recovery

Weight loss drugs should be covered by insurers, AMA says

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

There's no autism epidemic. It's an autism diagnosis epidemic

hotspot

knowledge

explore

Drug repurposing or repositioning? The language matters

The Readout: Lenmeldy, GLP

Activists slam private health insurers over coverage restrictions

A letter from the executive editor: STAT UnitedHealth investigation

Bright Health sells Medicare Advantage business to Molina

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Dobbs anniversary: the lost opportunity of abortion as health care

Study says nonprofit hospitals fall short in charity care spending

Peter Hotez and the public health issue of online harassment

FDA's naming rule on biosimilars has undermined competition

leisure time

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Washington mulls new rules to avert another Change Healthcare

Study suggests Covid rebound is far more common with Paxlovid than without

Washington mulls new rules to avert another Change Healthcare

Experimental asthma app from Apple and Anthem shows promise

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

knowledge

knowledge

hotspot